Free Trial
NASDAQ:TVRD

Tvardi Therapeutics (TVRD) Stock Price, News & Analysis

Tvardi Therapeutics logo
$37.46 +0.06 (+0.16%)
As of 09/23/2025 04:00 PM Eastern

About Tvardi Therapeutics Stock (NASDAQ:TVRD)

Advanced

Key Stats

Today's Range
$35.86
$38.92
50-Day Range
$22.74
$39.04
52-Week Range
$8.13
$40.77
Volume
50,248 shs
Average Volume
41,950 shs
Market Capitalization
$351.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.25
Consensus Rating
Buy

Company Overview

Tvardi Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

TVRD MarketRank™: 

Tvardi Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 748th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tvardi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Tvardi Therapeutics has a consensus price target of $64.25, representing about 71.5% upside from its current price of $37.46.

  • Amount of Analyst Coverage

    Tvardi Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Tvardi Therapeutics' stock forecast and price target.
    • Percentage of Shares Shorted

      11.06% of the float of Tvardi Therapeutics has been sold short.
    • Short Interest Ratio / Days to Cover

      Tvardi Therapeutics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
    • Change versus previous month

    • Dividend Yield

      Tvardi Therapeutics does not currently pay a dividend.

    • Dividend Growth

      Tvardi Therapeutics does not have a long track record of dividend growth.

    • Percentage of Shares Shorted

      11.06% of the float of Tvardi Therapeutics has been sold short.
    • Short Interest Ratio / Days to Cover

      Tvardi Therapeutics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
    • Change versus previous month

    • News Coverage This Week

      MarketBeat has tracked 2 news articles for Tvardi Therapeutics this week, compared to 1 article on an average week.
    • Search Interest

      9 people have searched for TVRD on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.
    • MarketBeat Follows

      Only 1 people have added Tvardi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
    • Insider Buying vs. Insider Selling

      In the past three months, Tvardi Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 3.10% of the stock of Tvardi Therapeutics is held by insiders.

    • Percentage Held by Institutions

      44.66% of the stock of Tvardi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Tvardi Therapeutics' insider trading history.
    Receive TVRD Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    TVRD Stock News Headlines

    Tvardi Therapeutics (TVRD) Receives a Buy from Piper Sandler
    China’s message to Trump
    Did China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of military power. Fighter jets, tanks, AI-guided drones — all paraded under the red flag, in front of Vladimir Putin, Kim Jong Un, and more than two dozen world leaders.tc pixel
    See More Headlines

    TVRD Stock Analysis - Frequently Asked Questions

    Tvardi Therapeutics' stock was trading at $29.09 on January 1st, 2025. Since then, TVRD shares have increased by 28.8% and is now trading at $37.46.

    Tvardi Therapeutics, Inc. (NASDAQ:TVRD) posted its earnings results on Thursday, August, 14th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.49. Tvardi Therapeutics had a negative net margin of 678.79% and a negative trailing twelve-month return on equity of 565.83%.

    Tvardi Therapeutics' top institutional investors include Slate Path Capital LP (7.52%), 683 Capital Management LLC (1.88%), Geode Capital Management LLC (1.20%) and Marshall Wace LLP (0.27%).

    Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Company Calendar

    Last Earnings
    8/14/2025
    Today
    9/23/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:TVRD
    Previous Symbol
    NASDAQ:TVRD
    CIK
    1346830
    Web
    N/A
    Employees
    80
    Year Founded
    2004

    Price Target and Rating

    High Price Target
    $78.00
    Low Price Target
    $52.00
    Potential Upside/Downside
    +71.5%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    4 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$70.87 million
    Net Margins
    -678.79%
    Pretax Margin
    -453.48%
    Return on Equity
    -565.83%
    Return on Assets
    -66.71%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    4.04
    Quick Ratio
    4.04

    Sales & Book Value

    Annual Sales
    $7.14 million
    Price / Sales
    49.21
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    ($3.02) per share
    Price / Book
    -12.40

    Miscellaneous

    Outstanding Shares
    9,380,000
    Free Float
    9,086,000
    Market Cap
    $351.37 million
    Optionable
    N/A
    Beta
    0.25

    Social Links

    Metaverse Stocks And Why You Can't Ignore Them Cover

    Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

    Get This Free Report

    This page (NASDAQ:TVRD) was last updated on 9/24/2025 by MarketBeat.com Staff
    From Our Partners